Request an appointment
Your path to clearer, brighter cognitive health begins here—with expert care, genuine warmth, and unwavering support. Contact us or request a call back today.
As the science of Alzheimer’s disease advances, a new generation of treatments is emerging that targets the underlying biology of the disease—not just the symptoms.
Among these, monoclonal antibody therapy has generated significant interest for its potential to slow the progression of early-stage Alzheimer’s disease.
In this article, we explain:
- What monoclonal antibody treatments are and how they work
- What results clinical trials have shown
- The current availability of these treatments in the UK
- How our clinic can support appropriate patients in exploring these options privately
Our goal is to provide clear, accurate and compassionate guidance for families navigating a diagnosis of early Alzheimer’s or mild cognitive impairment.
What Is Monoclonal Antibody Therapy for Alzheimer’s Disease?
Monoclonal antibodies are laboratory-designed proteins that bind to a specific target—in this case, amyloid-beta, a toxic protein that builds up abnormally in the brains of people with Alzheimer’s disease.
Why does this matter?
Amyloid buildup creates sticky plaques that disrupt communication between brain cells and trigger inflammation, ultimately leading to memory problems and cognitive decline.
These new therapies aim to:
- Detect and bind to amyloid in the brain
- Help the immune system clear it away
- Slow the biological process of Alzheimer’s disease
Which Monoclonal Antibody Drugs Are Making Headlines?
Lecanemab (Leqembi)
- Approved by the US FDA in 2023 for early Alzheimer’s disease
- Requires confirmed amyloid pathology via PET scan or blood test
- In clinical trials, slowed cognitive decline by 27% over 18 months
- Cleared significant amyloid deposits from the brain in most patients
Donanemab
- Another amyloid-targeting antibody currently under international regulatory review
- In phase 3 trials, slowed decline by up to 35% in people with early-stage Alzheimer’s
- Shown to clear amyloid more rapidly than some earlier treatments
Are these drugs a cure?
No. They do not reverse Alzheimer’s or stop it altogether—but they may offer a meaningful delay in progression, especially when started early.
How Do We Know These Treatments Work?
Large, well-designed clinical trials have demonstrated that monoclonal antibody therapies can:
- Reduce amyloid plaques seen on brain imaging
- Slow measurable cognitive decline in carefully selected patients
- Delay the loss of independence and daily functioning
However, these benefits are most apparent when:
- Treatment begins early, ideally at the mild cognitive impairment or mild dementia stage
- The patient has confirmed amyloid pathology
- Treatment is given consistently and monitored carefully
Can You Access These Alzheimer’s Treatments in the UK?
As of 2025, these monoclonal antibody drugs are:
- Not yet approved by NICE for NHS prescribing in the UK
- Not routinely available through NHS memory clinics
- Available privately or through clinical trials in select specialist centres
How private patients can access monoclonal antibody treatment in the UK:
- Through referral to centres involved in global early-access programmes
- By participating in research trials (strict eligibility applies)
- With private funding, and only if patients meet specific clinical criteria
At present, the costs of private treatment are significant, and ongoing monitoring (e.g. MRI scans) is mandatory due to the risk of side effects.
What Are the Potential Risks or Side Effects?
While these treatments are a scientific breakthrough, they are not risk-free.
A known side effect is Amyloid-Related Imaging Abnormalities (ARIA)—which includes:
- Temporary brain swelling (ARIA-E)
- Small areas of micro-bleeding (ARIA-H)
These side effects are usually mild and resolve on their own, but they can cause:
- Headache
- Dizziness
- Nausea or confusion in rare cases
This is why patients need careful screening, regular brain scans, and specialist supervision during treatment.
Could You or a Loved One Be Eligible?
These therapies are only suitable for a very specific group of patients:
- Diagnosed with mild Alzheimer’s disease or mild cognitive impairment (MCI)
- Have amyloid confirmed via scan or blood biomarker testing
- Are in good general health and able to attend regular infusions and monitoring
- Understand and accept the potential risks and limitations
We offer private diagnostic clarity assessments to help patients understand whether monoclonal antibody therapy could be an option.
How We Can Help
At our specialist memory and brain health clinic, we provide:
- Expert-led cognitive assessments
- Advanced Alzheimer’s blood testing for amyloid and tau biomarkers
- Access to MRI and PET imaging (if needed)
- Guidance on suitability for emerging treatments
- Referral to approved specialist centres offering monoclonal antibody therapy
We work with reputable partners both in the UK and abroad, and we offer a trusted clinical gateway to these new treatment pathways for appropriate patients.
While we do not currently administer monoclonal antibody therapy in-house, we can provide a comprehensive pre-treatment evaluation and ensure patients receive safe, informed referrals.
In Summary
Monoclonal antibody therapy marks a promising new chapter in Alzheimer’s treatment. While these therapies are not yet widely available on the NHS, they offer eligible patients a chance to slow disease progression when diagnosed early.
If you or someone close to you has been diagnosed with early Alzheimer’s, or if you’re concerned about memory loss, we’re here to help you explore all options—including access to the most cutting-edge therapies.
Book a Private Memory Assessment
To find out whether monoclonal antibody treatment may be right for you:
Phone: 0207 062 7248
Email: drsinghaisecretary@outlook.com
